Dr Carrie Tudor, Director of the ICN TB Project. attended the Guideline Development Group Meeting to revise the WHO treatment guidelines for rifampicin- and multidrug-resistant tuberculosis, 2018 update, in Switzerland, 16-20 July 2018. For over 20 years WHO has developed treatment guidance for drug-resistant TB to help countries address these challenges. The latest evidence-based guidance for the treatment of MDR/RR-TB was published by WHO in October 2016. The purpose of this meeting was to review the evidence for the treatment of MDR/RR-TB and make recommendations on the composition and duration of suitable treatment regimens.
Dr Carrie Tudor, Director of the ICN TB Project participated in the Association of Nurses in AIDS Care (ANAC) pre-conference session at the International AIDS Society meeting in Amsterdam. She was invited to participate in a panel session on TB care and treatment. ICN shared a booth with ANAC and promoted upcoming ICN events.
ICN has received a grant from the Stop TB Partnership’s highly competitive TB Reach mechanism to support development of the ICN Nursing Guide for Managing Side Effects to Drug-resistant TB Treatment. The ICN guide is being developed by nurses with experience in the clinical care and programmatic management of tuberculosis (TB) and drug-resistant tuberculosis (DR-TB) in both high- and low-resource settings. Nursing and DR-TB literature have been reviewed to establish best practice nursing assessment and intervention guidance. Nurses caring for patients with DR-TB have field tested the job aid and provided feedback which is being used to inform final content and format.